Portugal Coimbra AI detects early cognitive decline

That is the bigger investment story too: AI in healthcare is no longer just about administrative efficiency or flashy consumer apps. It is moving into high-stakes clinical workflows where accuracy, trust and reimbursement will decide which tools survive. The latest frustrations with consumer-facing health AI, including inaccurate food-tracking tools, are a reminder that healthcare users will not tolerate hallucinations or sloppy outputs. But the University of Coimbra’s work points to a more durable use case — one where AI supports clinicians rather than replacing them.

That distinction matters for companies built around medical data, diagnostics and AI-enabled care. Teladoc Health’s stock has been volatile and remains well below its recent peaks, while Tempus AI and Nvidia sit at the center of the broader AI-healthcare theme investors continue to price unevenly. Tempus, in particular, has seen sharp swings, with its shares recently trading near $65.86 after touching above $103 earlier in the period shown, and its 14-day RSI sitting around 61 — evidence of a stock that has rebounded but is still digesting a big move. Nvidia, meanwhile, remains the infrastructure winner whenever AI adoption expands into new verticals.

For long-term investors, the key question is not whether one university project changes the market overnight. It’s whether it reinforces a secular trend: AI is being pulled deeper into medicine because health systems need better screening, faster workflows and more personalized decision-making. That trend supports the case for companies that can combine data, clinical expertise and regulatory credibility — the hard parts of healthcare, not just the easy demos.

The risks are real. Medical AI must prove it can work across diverse populations, in different languages and under strict privacy rules. False positives can overwhelm doctors, while false negatives can be dangerous. Still, if Coimbra’s effort is a sign of where healthcare is headed, the long-term winners are likely to be the firms that turn AI from a novelty into a trusted clinical tool. For investors, that makes the healthcare-AI stack worth watching, not trading.